Suppr超能文献

在慢性丙型肝炎中,采用天然β干扰素诱导法通过抑制丙型肝炎病毒来恢复先天性和适应性免疫反应。

Restoration of innate and adaptive immune responses by HCV viral inhibition with an induction approach using natural interferon-beta in chronic hepatitis C.

作者信息

Kishida Y, Imaizumi N, Tanimura H, Haruna Y, Kashiwamura S, Kashiwagi T

机构信息

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Osaka Kaisei Hospital 1-6-10 Miyahara, Yodogawa-Ku, Osaka City, Osaka 532-0003, Japan.

出版信息

Clin Dev Immunol. 2012;2012:582716. doi: 10.1155/2012/582716. Epub 2012 Aug 27.

Abstract

Chronic hepatitis C (CHC) is a serious medical problem necessitating more effective treatment. This study investigated the hypothesis that an induction approach with nIFN-beta for 24 weeks followed by PEG-IFN-alpha+ribavirin (standard of care: SOC) for 48 weeks (novel combination treatment: NCT) would increase the initial virologic response rate and restore innate and adaptive immune responses in CHC. Seven CHC patients with a high viral load and genotype 1b were treated with NCT. Serum cytokine and chemokine levels were evaluated during NCT. NCT prevented viral escape and breakthrough resulting in persistent viral clearance of HCVRNA. IL-15 was increased at the end of induction therapy in both early virologic responders (EAVRs) and late virologic responders (LAVRs); CXCL-8, CXCL-10, and CCL-4 levels were significantly decreased (P < 0.05) in EAVR but not in LAVR during NCT, and IL-12 increased significantly (P < 0.05) and CXCL-8 decreased significantly (P < 0.05) after the end of NCT in EAVR but not in LAVR. NCT prevented viral breakthrough with viral clearance leading to improvement of innate and adaptive immunity resulting in a sustained virologic response (SVR). NCT (n = 8) achieved a higher SVR rate than SOC (n = 8) in difficult-to-treat CHC patients with genotype 1 and high viral loads.

摘要

慢性丙型肝炎(CHC)是一个严重的医学问题,需要更有效的治疗方法。本研究调查了这样一种假设:采用nIFN-β诱导治疗24周,随后使用聚乙二醇干扰素-α+利巴韦林(标准治疗方案:SOC)治疗48周(新型联合治疗方案:NCT),将提高慢性丙型肝炎的初始病毒学应答率,并恢复其固有免疫和适应性免疫应答。7例病毒载量高且基因型为1b的慢性丙型肝炎患者接受了新型联合治疗方案治疗。在新型联合治疗方案治疗期间评估血清细胞因子和趋化因子水平。新型联合治疗方案可防止病毒逃逸和突破,从而实现丙型肝炎病毒核糖核酸(HCVRNA)的持续病毒清除。在早期病毒学应答者(EAVR)和晚期病毒学应答者(LAVR)中,诱导治疗结束时白细胞介素-15(IL-15)均升高;在新型联合治疗方案治疗期间,早期病毒学应答者的CXC趋化因子配体8(CXCL-8)、CXC趋化因子配体10(CXCL-10)和C-C趋化因子配体4(CCL-4)水平显著降低(P<0.05),而晚期病毒学应答者则无此现象;在新型联合治疗方案结束后,早期病毒学应答者的白细胞介素-12显著升高(P<0.05),CXC趋化因子配体8显著降低(P<0.05),晚期病毒学应答者则无此现象。新型联合治疗方案可防止病毒突破并实现病毒清除,从而改善固有免疫和适应性免疫,实现持续病毒学应答(SVR)。在治疗困难的基因型1和病毒载量高的慢性丙型肝炎患者中,新型联合治疗方案(n = 8)的持续病毒学应答率高于标准治疗方案(n = 8)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/fad31e1fa91c/CDI2012-582716.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验